Latest news with #Mikael
_2025_05_30_14_25_57.jpg&w=3840&q=100)
GMA Network
3 days ago
- Entertainment
- GMA Network
Megan Young and Mikael Daez sing Backstreet Boys song as lullaby for newborn
Megan Young and Mikael Daez are only a week old into their new roles as parents but it seems the Kapuso couple know exactly what to do — with their makeshift knowledge. On Instagram, Mikael posted a video of the two of them soothing their newborn with the Backstreet Boys song "I Want It That Way." Mikael was holding the baby, and Megan was gamely singing and dancing along and when they finished, the new dad told their baby, "that is what you call beautiful singing." "Vintage music," Megan piped in. "You're millennials but forgot all the usual lullabies," Mikael wrote in the video as he added in the caption, "kanya-kanyang diskarte para mapatahan ang baby." According to Mikael, at just a few days, they're just trying to figure out what works for their baby boy. "Instinctively napunta sa BSB bigla ang lullaby repertoire ko, si Bonez papuntang Doechii, sa tingin ko," he added. Megan and Mikael announced the birth of their firstborn last Wednesday. They tied the knot in 2020 in intimate ceremonies and in December 2024, announced they were expecting their first child, a baby boy. — LA, GMA Integrated News
Yahoo
08-05-2025
- Entertainment
- Yahoo
TrustNordisk Adds ‘Unraveled' by ‘Becoming Astrid's' Pernille Fischer Christensen, Reveals First Image Ahead of Cannes Market (EXCLUSIVE)
Ahead of Cannes market, Scandinavia's leading sales agent TrustNordisk has released a fresh still from Pernille Fischer Christensen's drama 'Unraveled' ('Vores Løfte') which just wrapped filming for Nordisk Film Production Denmark. A Berlinale regular, from her 2006 breakthrough prize-winning debut 'A Soap' to the Astrid Lindgren biopic 'Becoming Astrid' (2018), picked up by Music Box for the U.S., Christensen's 'Unraveled' marks her anticipated return to the silver screen after her TV drama immersion that notably took in co-directing DR's acclaimed 'Cry Wolf.' More from Variety Chechen Documentary 'Imago' Debuts Clip Ahead of Cannes Premiere, Rediance Handles Sales (EXCLUSIVE) Spanish Comedy Icon Fernando Colomo's 'The Delights of the Garden' Swooped on by Latido Films in the Run-up to Cannes (EXCLUSIVE) How Trump's Tariffs Could Derail the Cannes Film Festival The upcoming Danish pic stars Danica Curcic ('The Chestnut Man,' 'Out Stealing Horses') as Maria, a former elite swimmer and famous sports commentator whose life unravels when her beloved husband Mikael (Lars Ranthe from 'Another Round'), her former coach and father of their daughter, is suddenly suspected of sexual abuse. Sparking the scandal and media interest is the revelation in an upcoming book, of a young girl's misguided infatuation for her swimming coach, with rumors suggesting that Mikael is the man in question. What fuelled Christensen's interest for the subject a few years back, was #MeToo, 'one of the greatest things that ever happened to us women since free abortion and our right to vote' says Christensen. 'But, I'm also a person with a lot of empathy, so I started to wonder how it would feel for the man accused of sexual harassment, what it would be like to be his wife and kids.' For the director who's often put family at the core of her work, her sixth feature is first and foremost 'a drama about a woman who is forced to re-examine her marriage, the deep love for her husband, as she tries to keep together her family and protect her daughter from the media frenzy that arises,' explains the helmer who for the first time penned her script fully on her own, without co-writer Kim Fupz Aakeson. 'Because of the subject matter, which deals with a woman reflecting on her couple, on herself and regaining control of her narrative, I felt I had to take full control over the material.' As Christensen tells Variety, key elements that helped her build and refine the script were thorough research, interviews with men who had been accused of sexual harassment and their families, and discussions with the key cast to capture the authenticity in their performance. Christensen said she is currently fine-tuning the tone and 'thriller-ish' element around the sexual allegations – with editor My Thordal ('Families Like Ours,' 'The Kingdom'), actress-turned composer Rebekka Karijord ('Songs of Earth,' 'All the Old Knives') and cinematographer Joe Maples ('Blackwater,' 'The Hunt for a Killer'). TrustNordisk's managing director Susan Wendt said: 'The film touches on a variety of subjects through a single storyline, telling a gripping and emotional but also universal and timely story. 'Unraveled' is a very character-driven film, which is one of Pernille's big strengths and I'm sure that she with this film once again will captivate audiences around the world.' The pic, produced by Mette Høst Hansen & Tomas Radoor for Nordisk Film Production, is set to launch in Denmark in spring 2026. For Cannes, TrustNordisk's strong slate also takes in Anders Thomas Jensen's highly-anticipated 'The Last Viking' starring Mads Mikkelsen, with fresh scenes to be unveiled at a promo-reel presentation, with half a dozen upcoming titles. Two films will screen at the market: the Swiss-German hospital drama 'Late Shift,' which collected solid reviews on the back of its Berlinale Special Gala presentation and Norwegian doc feature and series 'Fighter,' showcased at CPH:DOX and Series Mania. Commenting on the state of the market ahead of Cannes kick off, seasoned sales agent Wendt said: 'It is hard to say what the market will be like. The buyers are surely more selective and careful, but if you have the right projects, they are still there, paying good prices. The question is always what they are looking for. But TrustNordisk comes to Cannes with a range of exciting new projects and a very diverse line-up with features and series from both new and established filmmakers ranging from major dramas, crime, feel-good dramedies to monster action and animation and we look forward to presenting all of them to the international market.' Best of Variety New Movies Out Now in Theaters: What to See This Week Emmy Predictions: Talk/Scripted Variety Series - The Variety Categories Are Still a Mess; Netflix, Dropout, and 'Hot Ones' Stir Up Buzz Oscars Predictions 2026: 'Sinners' Becomes Early Contender Ahead of Cannes Film Festival
Reuters
12-03-2025
- Business
- Reuters
Northvolt bankruptcy strikes blow to Sweden's northern boom town
STOCKHOLM, March 12 (Reuters) - The bankruptcy of battery cell maker Northvolt, once the leader of Sweden's green industrial boom, is a huge blow to the country's north and particularly the small town of Skelleftea. The town, founded 180 years ago as a mining city to serve the surrounding mineral-rich mountains, had long been in decline when Northvolt decided to build its main factory there in 2017. Northvolt, with its 3,000 workers, is the biggest employer in the town of around 40,000 people, where there is also a diverse manufacturing sector covering areas such as metals, forestry, plastics, rubber and energy. Spurred by Sweden's green boom, described locally as the "Northvolt-effect", Skelleftea grew and invested more per capita than any other municipality in Sweden in 2022, building homes and schools and expanding its harbour. The bankruptcy, one of the biggest in Swedish corporate history, will alter the future of the town, which is cloaked in snow and darkness for much of the winter before experiencing almost 24 hours of daylight in summer. "It's a disaster," Mikael, who only wanted to be identified by his first name, told Reuters. "It's a big blow to Skelleftea and for everyone who lives here," he said, adding that a lot of the enthusiasm over the green boom in the last decade had disappeared. "This is a reality check." Lorents Burman, the mayor of Skelleftea, called on the government to act quickly to provide financial support to the battery operation and help find a new owner. "It is of course incredibly heavy news and a nightmare," he told Reuters. "The loss of human capital would be huge. There is no other place in Europe where there is a combined expertise of 3,000 people who can build batteries," he said. Northvolt's problems have sent shockwaves across Sweden's north, with several local authorities seeking more financial support from the central government almost 500 miles (805 km) away. "This was not the message that we hoped for," Minister of Enterprise and Energy Ebba Busch told a news conference. She did not announce any new financial support for the failing business but said she hoped a new owner would take over the production. "I hope it will be possible to ensure that the business is kept running during the bankruptcy proceedings," she said, adding that she would travel to Skelleftea on Thursday. Lena Lundgren, local union representative for IF Metall, which has 1,800 members at Northvolt in Skelleftea, told Reuters that the union had established a crisis centre for its local members. "It's important that they know that they are not alone in this," she said.
Associated Press
05-03-2025
- Health
- Associated Press
Orbis Medicines Names Veteran R&D Leader Mikael Dolsten Board Chair
Orbis Medicines, a leader in oral macrocycle drug discovery, today announces the appointment of Mikael Dolsten, M.D., Ph.D., former Chief Scientific Officer, President, Pfizer Research & Development, as Chairperson of the Board of Directors. In more than 15 years at Pfizer, Dr. Dolsten oversaw the development and approval of more than 35 therapies and vaccines, and moved more than 100 drug candidates into clinical development. 'Mikael has a long and successful track record overseeing the development of blockbuster therapies and vaccines from discovery through approval, and shares Orbis' vision of embracing macrocycle-based medicines to unlock new treatment options for patients,' said Orbis Chief Executive Officer Morten Graugaard. 'Mikael's guidance will be pivotal as we advance our mission to provide novel, high-value oral alternatives to existing biologics, which have tremendous potential to address the needs of patients with chronic diseases and to streamline the healthcare system.' Prior to his tenure at Pfizer, Dr. Dolsten served in leadership roles at AstraZeneca, Boehringer Ingelheim, Pharmacia, and Wyeth Pharmaceuticals. Dr. Dolsten has served on several public boards in the US and Europe and has vast experience in business development, including 10 different mergers and acquisitions. 'By creating oral alternatives to biologics such as antibodies and peptides and designing oral drugs for hard-to-drug intracellular targets, the work Orbis Medicines is doing will dramatically expand access to treatment for patients suffering from many chronic and devastating diseases, which is truly the next frontier in drug discovery,' said Dr. Dolsten. 'What the Orbis Medicines team led by Morten are achieving in the field of oral macrocycle medicines positions the company to be a disruptor of the biologics market. I believe Orbis Medicines has the potential to become the leading oral macrocycles and oral biologics biotech company.' Dr. Dolsten's accomplishments include the introduction of a new class of oral medications for autoimmune diseases, the development and approval of targeted anaplastic lymphoma kinase (ALK) inhibitors in non-small cell lung cancer and Pfizer's rapid R&D response to the COVID-19 pandemic (see 'Note to Editors' below for more information). Orbis Medicines is pioneering the systematic discovery and development of targeted, orally available macrocycles for diseases and targets traditionally treated with biologics. Orbis develops compounds known as n Cycles, which can address a wide range of validated protein targets with unique oral bioavailability and membrane permeability features. About Orbis Medicines Orbis Medicines is pioneering a new era for oral macrocycle drug discovery. Its n Gen platform systematically delivers macrocycle candidates, termed n Cycles. These are optimized for oral bioavailability, which has historically hindered therapeutic development of this versatile class of molecules. Orbis' pipeline is initially focused on n Cycle candidates against targets validated by blockbuster biologic drugs delivered by injection. Proof-of-concept of Orbis' work has been published in Nature Communications and Nature Chemical Biology. The company has raised €116 million in venture funding to date, including a €90 million series A round led by NEA with new investors Lilly Ventures, Cormorant, EIFO and existing investors Forbion and Novo Holdings. Orbis is located in Copenhagen, Denmark and Lausanne, Switzerland. For more information, please visit: About n Gen n Gen is Orbis Medicines' technology platform for generating n Cycles, a new class of fully synthetic macrocycle compounds optimized for oral bioavailability and membrane permeability. It consists of multiple proprietary integrated elements in a 'lab in a loop' system starting with hit finding libraries of 100 billion compounds. The highly automated chemistry-based n Gen platform can synthesize and analyze up to 100,000 distinct synthetic macrocycles in weeks, allowing the company to discover candidates with the right properties to enable oral dosing and intracellular targeting. The scale and quality of the data produced from these real compounds, paired with machine learning, creates an industry-leading platform that de-risks and accelerates development. Note to Editors Notable accomplishments of Mikael Dolsten, M.D., Ph.D., during his tenure as Chief Scientific Officer, President, Pfizer Research & Development Introduced a new class of oral medications for autoimmune diseases dominated by biologics, including first-in-class JAK inhibitor Xeljanz (tofacitinib) for rheumatoid arthritis & ulcerative colitis, first-in-class Janus kinase 1 (JAK1) inhibitor Cibinqo (abrocitinib) for atopic dermatitis and the tyrosine kinase expressed in hepatocellular carcinoma/Janus kinase 3 (Tec/JAK3) drug Litfulo (ritlecitinib) for alopecia areata. Oversaw the development and approval of targeted ALK inhibitors in the highly competitive non-small cell lung cancer (NSCLC) market, including first-in-class ALK inhibitor Xalkori (crizotinib) and third-generation ALK inhibitor Lorbrena (lorlatinib). Other major drug approvals during Dr. Dolsten's tenure at Pfizer included the breast cancer drug Ibrance (palbociclib), the myeloma drug Elrexfio (elranatamab-bcmm), the poly (ADP-ribose) polymerase (PARP) inhibitor Talzenna, the vascular endothelial growth factor receptor (VEGFR) inhibitor Inlyta (axitinib), the oral anti-coagulant Eliquis (apixaban), the transthyretin amyloid stabilizing drug Vyndaqel (tafamadis), the Prevnar 20 vaccine and the RSV vaccine Abrysvo. Spearheaded Pfizer's rapid R&D response to the COVID-19 pandemic, receiving emergency use authorization and subsequently full approval for the oral antiviral therapy Paxlovid (nirmatrelvir/ritonavir) and for COVID-19 mRNA vaccine Comirnaty, in partnership with BioNTech. Dr. Dolsten announced his retirement from Pfizer in July 2024. SOURCE: Orbis Medicines Copyright Business Wire 2025. PUB: 03/05/2025 01:00 AM/DISC: 03/05/2025 12:59 AM
